Meta-analysis finds vonoprazan-based therapies achieve 94% H. pylori eradication in Asian populations

This systematic review, meta-analysis, and meta-regression examined the efficacy of vonoprazan-based therapies for Helicobacter pylori eradication in Asian populations. The analysis included 7,498 patients, though specific study settings and follow-up durations were not reported. The population was exclusively Asian, limiting generalizability to other ethnic groups. The study design aggregated data from multiple studies to compare vonoprazan-amoxicillin regimens against proton pump inhibitor (PPI)-based therapies, though the specific dosing protocols and durations for either intervention were not detailed in the provided data.

The intervention consisted of vonoprazan combined with amoxicillin, administered in dual, triple, or quadruple therapy regimens. The comparator was standard PPI-based therapies, though the exact PPI types, doses, and combination antibiotics were not specified. The primary outcome was eradication rate, measured across different therapy regimens. For dual therapy with vonoprazan-amoxicillin, the eradication rate was 0.92 (95%CI: 0.90-0.95). Triple therapy achieved 0.93 (95%CI: 0.91-0.95), while quadruple therapy showed the highest rate at 0.96 (95%CI: 0.93-0.99). The overall eradication rate for vonoprazan-based therapies was 0.94 (95%CI: 0.91-0.96).

Key secondary outcomes included risk differences comparing vonoprazan-based therapies to PPI-based therapies. The overall risk difference was 0.06 (95%CI: 0.02-0.09), indicating a 6% absolute increase in eradication rates with vonoprazan. For specific regimens: dual therapy showed a risk difference of 0.03 (95%CI: -0.02-0.08), triple therapy 0.07 (95%CI: 0.02-0.12), and quadruple therapy 0.04 (95%CI: 0-0.07). Meta-regression analyses revealed that age significantly influenced therapy effectiveness (p=0.006), while BMI did not (p=0.411).

Safety and tolerability findings were not reported in the provided data. No information was available regarding adverse event rates, serious adverse events, discontinuations due to side effects, or overall tolerability profiles. This represents a significant gap in the evidence, as safety considerations are crucial for clinical decision-making when comparing acid-suppressing therapies.

When compared to prior landmark studies in H. pylori eradication, these results suggest vonoprazan-based therapies may offer modest improvements over traditional PPI-based regimens, which typically achieve eradication rates around 85-90% in various populations. The 94% overall eradication rate and 6% absolute risk difference are clinically meaningful, though the magnitude of benefit varies by regimen. The finding that age influences effectiveness aligns with existing literature showing differential responses in older populations.

Key methodological limitations include the exclusive focus on Asian populations, which limits generalizability to other ethnic groups. The meta-analysis did not report specific study settings, follow-up durations, or detailed dosing protocols. The absence of safety data represents another significant limitation. Additionally, the analysis did not specify which studies were included, their quality assessments, or potential publication biases. The lack of absolute numbers for eradication events prevents calculation of more precise effect measures.

Clinical implications suggest that vonoprazan-based therapies, particularly quadruple and triple regimens, may offer modest advantages over PPI-based therapies for H. pylori eradication in Asian populations. The 6% absolute risk difference translates to a number needed to treat of approximately 17 to achieve one additional eradication compared to PPIs. However, clinicians should consider the lack of safety data and the population-specific findings when making treatment decisions. The influence of age on effectiveness suggests personalized approaches may be warranted.

Unanswered questions include the safety profile of vonoprazan-based therapies compared to PPIs, optimal dosing and duration regimens, cost-effectiveness analyses, and applicability to non-Asian populations. The mechanisms behind age-related differences in effectiveness require further investigation. Additionally, long-term outcomes beyond eradication rates, such as ulcer healing rates and prevention of complications, were not addressed in this analysis.